ShareValue.ai

ShareValue scores for AMRN: Valuation 69, Quality 64, Growth 37, Health 63.

AMRN
NASDAQ

Amarin Corporation PLC

$15.46(-1.72%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

7% to 17%
Valuation
69
Fair Value
Price vs Value
Quality
64
Moderate
Business Strength
Growth
37
Weak
Revenue & Earnings
Health
63
Moderate
Financial Stability
Momentum
57
Neutral
Price Trend

Company Details

About

Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally through wholesalers, selected regional wholesalers, and retail and mail order pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland. Address: One Central Plaza, Dublin, Ireland, D02 K7K5

Score Analysis

AI Investment Thesis

Data as of:Jul 9, 2026
|
Last calculated:Jul 9, 2026